Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of October 2019. The document serves as a transaction notification regarding a specific insider trading event rather than a comprehensive financial report.
Key Financial Metrics
The filing does not provide aggregate financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It contains only transaction-specific data:
- Instrument: American Depositary Shares (ADSs), ISIN: US37733W1053.
- Transaction Price: $42.2439 per ADS.
- Transaction Volume: 25,407 ADSs.
- Total Value: Approximately $1,073,300 (calculated from price and volume).
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details a single acquisition of ADSs by a Person Discharging Managerial Responsibilities (PDMR) following the reinvestment of dividends.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. The transaction was executed on October 11, 2019, on the New York Stock Exchange (XNYS) as part of the Deferred Annual Bonus Plan Post-Tax.
Investor Verification Points
- Verify the identity of the PDMR: Mr. B McNamara, CEO of GSK Consumer Healthcare.
- Confirm the transaction nature: Acquisition of ADSs via dividend reinvestment, not an open-market purchase.
- Note that this filing does not reflect the company's overall financial performance for the period.